This week, Singapore's state-owned investment company Temasek released its FY2020 report card, stating that in the fiscal year ending March 31, 2020, Temasek's portfolio netted S$306 billion (roughly Rs. 1.53 trillion), with the percentage of its portfolio in China rising to 29%, surpassing that of Singapore (24%). This is reportedly the first time that the investment giant's position in China has exceeded its investment in Singapore's home market.
And what are the dynamics of the most capital-hot SSE TechCard in China this week? Here are the details:
01
The first batch of 4 Sci-Tech 50 ETFs were formally approved by the Securities and Futures Commission (SFC)
On September 11, the first batch of ETF products tracking the Sci-Tech 50 index were formally approved by the SFC, which are Huaxia Kechuang 50 ETF, Efonda Kechuang Board 50 ETF, Huatai Perry Kechuang 50 ETF, ICBC Credit Suisse Kechuang 50 ETF, and their offering dates are expected to be on the 18th or 22nd of this month. From the product custodian point of view, Huaxia Fund's Sci-Tech 50 ETF is hosted at China Merchants Bank, Efonda Fund's products are hosted at ICBC, and ICBC Credit Suisse and Huatai Perry's Sci-Tech 50 ETFs have chosen to be hosted at Agricultural Bank of China (ABC) and China Construction Bank (CCB), respectively.
It is understood that the Sci-Tech 50 index is based on December 31, 2019 as the base date, with 1,000 points as the base point. As of September 11, the index has been running for more than nine months, up 32.32%, and the money-making effect exceeds the CSI 300 and CSI 500 gains over the same period, outperforming the mainstream index.
02
Warner Pharmaceuticals: Positive Response to the Patent Dispute over Zuo Ou Nizole Tablets
On September 7, Warner Pharmaceuticals filed a lawsuit against CCTV. The company submitted a reply to the Q&A letter on the KTB audit, in which it positively answered questions about the issuer's shareholding structure, the basic situation of directors and supervisors, etc., core technology, research and development capabilities.
For the above patent dispute, Warner Pharmaceuticals said: the company only began to produce and sell the product of Zuo Ou nitrozole tablets in fiscal year 2019, with sales revenue of 631,500 yuan. Due to the small amount of litigation involved in the dispute case, it will not have a significant impact on the company's continuing operations.
Revenue from sales of core products of Warner Pharmaceuticals
03
Keqian Bio: set the application price of 11.69 yuan/share
On September 11, Keqian Bio officially launched the TechFront IPO subscription. The company's total number of shares issued about 105 million shares, online issuance of about 16 million shares, the issuance of P/E ratio of 26.23 times, the subscription price of 11.69 yuan / share, a single account subscription limit of 16,000 shares.
Keqian Biological is a biopharmaceutical enterprise focusing on the research and development of veterinary biological products, production, sales and technical services for animal epidemic prevention, and its main products are swine vaccines and poultry vaccines. In this IPO on the Science and Technology Board, TechFront Bio intends to raise 1.747 billion yuan for seven projects, including the industrialization and construction of animal biological products. It is expected to officially ring the bell in the KICC later this month.
According to the prospectus disclosure, in the first half of 2020, Keqian Biological realized revenue of 355 million yuan, up 23.86% over the same period of the previous year; net profit of 183 million yuan, up 18.14% over the same period of the previous year.
04
Chuang'er Bio: Answer to the question about the "pharmaceutical manufacturing" industry positioning
On September 11, Chuang'er Bio submitted a report on the first round of questions of the Science and Technology Board (STB). The first round of questions on the Science and Technology Innovation Board after the reply to the views of the issuer has been listed on the New Third Board of the basic situation, core technology, industry positioning and financial data and other issues to answer questions.
It is worth mentioning that the answer to the question about the industry positioning of Chuanger Biological "pharmaceutical manufacturing", said the company's main products collagen dressings, collagen sponges, biological skincare products, the core material for active collagen, which collagen dressings are mainly used for skin allergies, laser, photonics, post-surgical wound repair auxiliary treatment, and the company's main product is collagen. Post-operative wound repair auxiliary therapy, collagen sponge is mainly used for skin bleeding wound hemostasis and open injury wound repair, biological skin care products are mainly used for skin barrier care, enhance the skin healing ability, etc., the industry belongs to the "C27 Pharmaceutical Manufacturing Industry" under the category of "C277 Hygiene materials and medical supplies manufacturing" category.
05
WPMI: Responding to the question of "the failure to effectively transform the advantages of technological leadership into the advantages of market leadership".
On September 11th, WPMI submitted its response to the implementation letter of the Listing Opinion of the Audit Center, as well as the draft for the meeting of the China Science and Technology Innovation Board (CSTB). During the meeting, WPMI answered questions on the issue of "WPMI's failure to effectively transform its technological leadership in the use of cesium iodide direct growth technology in medical flat panel detectors into a market-leading advantage".
Its reply said: "WPMI's business growth lagged behind that of its major domestic competitors because the domestic market is still dominated by the gadolinium thioglobinium oxide (GTO) technology route, coupled with the relatively high cost and price of the product, and the late introduction of the product to the market, which resulted in the failure to effectively transform its technological leadership into a first-mover advantage in the market. In the future, it is necessary to further improve the sales capacity. "
Other Newsflash
On September 7, Yafiron Bio submitted its application for registration for listing on the KTC. This is another IVD company that will be listed on the KTC after Ambipin, SciHyde, and Shengxiang Bio. The IPO intends to issue no more than 41 million shares in public offering and raise up to 73.3 million dollars.
On September 8, Huitai Medical passed the SCOTUS meeting. This is a complete coronary access and electrophysiology medical devices as the leading medical device company, peripheral vascular and neurointerventional medical devices as the focus of development. The company's Cochrane IPO intends to issue no more than 16.67 million shares of stock in a public offering to raise $84,000,000 in capital.
On September 9, the registration of Aladdin Biochemistry's Sci-Tech IPO took effect. This is a scientific research reagent manufacturer, the business covers high-end chemistry, life sciences, analytical chromatography and materials science four areas, while supporting a small number of experimental consumables. The IPO intends to issue no more than 25,233,400 shares in a public offering, raising $433,000,000 in capital.